BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cejemly (Sugemalimab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cejemly (Sugemalimab)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07247227-2747@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Cejemly (Sugemalimab): Phase na readout est. (NCT07247227)
DESCRIPTION:Cejemly (Sugemalimab)\, phase na\, Non-Small Cell Lung Cancer.\
 nStudy: Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC\n
 Estimated primary completion: May 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sugemalimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07247227
URL:https://assetmemo.bio/drug/sugemalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06217757-2747@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Cejemly (Sugemalimab): Phase 1/2 readout est. (NCT06217757)
DESCRIPTION:Cejemly (Sugemalimab)\, phase 1/2.\nStudy: Safety and Tolerabil
 ity of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of 
 SLFN-11 Positive ES-SCLC\nEstimated primary completion: 31 October 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sugemalimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06217757
URL:https://assetmemo.bio/drug/sugemalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06987734-2747@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cejemly (Sugemalimab): Phase 2 readout est. (NCT06987734)
DESCRIPTION:Cejemly (Sugemalimab)\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemal
 imab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer
  Patients\nEstimated primary completion: 31 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/sugemalimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06987734
URL:https://assetmemo.bio/drug/sugemalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05700448-2747@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Cejemly (Sugemalimab): Phase 3 readout est. (NCT05700448)
DESCRIPTION:Cejemly (Sugemalimab)\, phase 3.\nStudy: Study of Sugemalimab (
 or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell 
 Lymphoma\nEstimated primary completion: December 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sugemalimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05700448
URL:https://assetmemo.bio/drug/sugemalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
